The Conversation (0)
PBR reports that Canada-based drug maker Valeant Pharmaceuticals International (NYSE:VRX, TSX:VRX) has inked an agreement to acquire the global eye health company Bausch + Lomb Holdings Incorporated, in a cash deal valued at $8.7bn.
PBR reports that Canada-based drug maker Valeant Pharmaceuticals International (NYSE:VRX, TSX:VRX) has inked an agreement to acquire the global eye health company Bausch + Lomb Holdings Incorporated, in a cash deal valued at $8.7bn.
As quoted in the market news:
Around $4.5bn, from the total cash consideration, will be given to Warburg Pincus’ led investor group and the remaining $4.2bn will be used to refund Bausch + Lomb’s outstanding loans.
Valeant chairman and CEO J Michael Pearson said that the acquisition will boost its capabilities in ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments.
Click here for the full news story by Pharmaceutical Business Review (PBR)